Virologic Response and Safety of Ibuzatrelvir, A Novel SARS-CoV-2 Antiviral, in Adults With COVID-19
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciae529 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Mahta Mortezavi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Research and Development, Pfizer Inc, New York, New York, USA. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, COVID-19 Drug Treatment. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Inc.
Abstract (Originalsprache)
Background
Despite effective vaccines and treatments for COVID-19, clinical burden persists. An unmet need exists for additional effective agents with safety profiles allowing use across a broad population. Ibuzatrelvir is an orally bioavailable SARS-CoV-2 Mpro inhibitor with demonstrated in vitro antiviral activity and low potential for safety concerns, including drug–drug interactions.
Methods
This phase 2b, double-blind, randomized clinical trial enrolled US adults aged 18 to <65 years with symptomatic COVID-19 and no risk factors for severe disease. Participants were randomized 1:1:2:2 to receive 100, 300, or 600 mg ibuzatrelvir or placebo orally twice daily for 5 days. Nasopharyngeal specimens were collected on days 1 (baseline), 3, 5, 10, 14, and 21; adverse events (AEs) were recorded through day 33. The primary end point was change in SARS-CoV-2 RNA level (viral load [VL]) from baseline to day 5 among participants with baseline VL ≥4 log10 copies/mL.
Results
Of 240 enrollees, 237 received ≥1 dose; 199 were included in the primary analysis. Placebo-adjusted least squares mean (80% confidence interval) change from baseline in VL (log10 copies/mL) at day 5 was significant across all doses: 100 mg, ‒0.7 (‒1.1 to ‒0.3) log10 copies/mL, P = .02; 300 mg, ‒0.8 (‒1.3 to ‒0.3), P = .01; and 600 mg, ‒1.2 (‒1.5 to ‒0.8), P < .0001. AEs occurred in similar percentages of participants across groups. No deaths from any cause or treatment-related serious AEs occurred through day 33, and no participants reported dysgeusia.
Conclusions
All 3 ibuzatrelvir doses were associated with robust antiviral activity and an acceptable safety profile, supporting continued clinical development. Clinical Trials Registration NCT05799495.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pfizer Research and Development, Pfizer Inc, New York, New York, USA.
- Pfizer Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA.
- Pfizer Research and Development, Pfizer Inc, Collegeville, Pennsylvania, USA.
- Pfizer Research and Development, Pfizer Inc, Pearl River, New York, USA.
- Pfizer Research and Development, Pfizer Inc, Groton, Connecticut, USA.
Förderung
- Pfizer Inc
Zitieren
APA
Mortezavi, M., Sloan, A., Singh, R. S. P., Chen, L. F., Kim, J. H., Shojaee, N., Toussi, S. S., Prybylski, J., Baniecki, M. L., Bergman, A., Banerjee, A., Allerton, C., & Alami, N. N. (2025). Virologic Response and Safety of Ibuzatrelvir, A Novel SARS-CoV-2 Antiviral, in Adults With COVID-19. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae529
Vancouver
Mortezavi M, Sloan A, Singh RSP, Chen LF, Kim JH, Shojaee N, et al. Virologic Response and Safety of Ibuzatrelvir, A Novel SARS-CoV-2 Antiviral, in Adults With COVID-19. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae529
BibTeX
@article{Mortezavi2025,
author = {Mortezavi, Mahta and Sloan, Abigail and Singh, Ravi Shankar P and Chen, Luke F and Kim, Jin Hyang and Shojaee, Negin and Toussi, Sima S and Prybylski, John and Baniecki, Mary Lynn and Bergman, Arthur and Banerjee, Anindita and Allerton, Charlotte and Alami, Negar Niki},
title = {Virologic Response and Safety of Ibuzatrelvir, A Novel SARS-CoV-2 Antiviral, in Adults With COVID-19},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciae529}
}
EUVIMED